British Journal of Anaesthesia, 2002, Vol. 89, No. 2 251-253
© 2002 The Board of Management and Trustees of the British Journal of Anaesthesia
Clinical Investigations |
Plasma concentration of ropivacaine after intercostal blocks for video-assisted thoracic surgery
1 Department of Anaesthesiology and Intensive Care Medicine, Hospital of the Philipps-University, Baldingerstrasse, D-35033 Marburg, Germany. 2 Department of Anaesthesiology and Intensive Care Medicine, Hospital of the Christian-Albrechts University, Schwanenweg 21, D-24105 Kiel, Germany*Corresponding author
Background. Absorption of local anaesthetics following intercostal blocks is rapid. Therefore, plasma concentrations of ropivacaine during intercostal blocks with ropivacaine 2, 5, 7.5 and 10 mg ml1 (ropivacaine 5 ml injected into each of four intercostal spaces) in patients undergoing video-assisted thoracic surgery were determined.
Methods. After informed consent and ethics committee approval, 64 patients were randomly allocated to four groups for intercostal nerve block (ropivacaine 2, 5, 7.5 or 10 mg ml1 at the end of surgery). Central (mixed) venous and arterial plasma samples were collected before the start of intercostal application, and 2, 5, 10, 15, 20, 30, 45, 60 and 90 min afterwards. Plasma concentrations of ropivacaine were measured by high performance liquid chromatography.
Results. Maximum venous plasma concentrations occurred after the mean times of 10.7 (range, 515), 10.8 (520), 11.3 (520) and 12.2 (545) min, respectively for each group. The groups had mean concentrations of 1.3 (SD, 0.6; range, 0.32.3), 2.1 (1.0; 0.54.5), 2.4 (1.0; 1.25.1) and 2.5 (0.9; 1.75.6) µg ml1, respectively. Maximum arterial plasma concentration following 1.0% ropivacaine occurred after 16 (545) min with a mean of 2.3 (0.6; 1.53.6) µg ml1. No signs of central nervous system or cardiac toxicity were observed.
Conclusions. After intercostal blocks the absorption of ropivacaine is rapid compared with other techniques for regional anaesthesia and results in relatively high venous and arterial plasma concentrations, especially if a dose of 100 mg or more is used.
Br J Anaesth 2002; 89: 2513